Skip to main content

Advertisement

SpringerLink
Log in

Rheumatoid arthritis in 2013

Translational medicine in RA—time for change

  • Year in Review
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

With every passing year, research on the pathogenesis of rheumatoid arthritis benefits from discoveries in other scientific fields. Three of the best examples that illustrate the benefit of such interdisciplinary bridges and the effects they have on our understanding of rheumatoid arthritis are presented here.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Translational medicine and clinical development.

References

  1. Miossec, P. & Kolls, J. K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug Discov. 11, 763–776 (2012).

    Article  CAS  Google Scholar 

  2. Nie, H. et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat. Med. 19, 322–328 (2013).

    Article  CAS  Google Scholar 

  3. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238 (2006).

    Article  CAS  Google Scholar 

  4. McGovern, J. L. et al. TH17 cells are restrained by TREG cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum. 64, 3129–3138 (2012).

    Article  CAS  Google Scholar 

  5. Alzabin, S. et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the TH17 pathway. Ann. Rheum. Dis. 71, 1741–1748 (2012).

    Article  CAS  Google Scholar 

  6. Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110, 3507–3512 (2013).

    Article  CAS  Google Scholar 

  7. Lee, J. C. et al. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 155, 57–69 (2013).

    Article  CAS  Google Scholar 

  8. Turrel-Davin, F. et al. FoxO3a involved in neutrophil and T cell survival is overexpressed in rheumatoid blood and synovial tissue. Ann. Rheum. Dis. 69, 755–760 (2010).

    Article  CAS  Google Scholar 

  9. Gregersen, P. K. & Manjarrez-Orduño, N. FOXO in the hole: leveraging GWAS for outcome and function. Cell 155, 11–12 (2013).

    Article  CAS  Google Scholar 

  10. Miossec, P. et al. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann. Rheum. Dis. 70, 1713–1718 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Immunology and Rheumatology and the Immunogenomics and Inflammation Research Unit EA 4130, University of Lyon, Hôpital Edouard Herriot, 5 Place d'Arsonval, Lyon Cedex 03, 69437, France

    Pierre Miossec

Authors
  1. Pierre Miossec
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre Miossec.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miossec, P. Translational medicine in RA—time for change. Nat Rev Rheumatol 10, 74–76 (2014). https://doi.org/10.1038/nrrheum.2013.204

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2013.204

  • Springer Nature Limited

This article is cited by

Search

Navigation